EN
HI
Summary
As of 18 Sep, 2026, Marksans Pharma stock price is ₹319.7. During the trading session, the stock has moved between an intraday low of ₹312.95 and an intraday high of ₹322.50. Over the last 52 weeks, Marksans Pharma has traded between ₹155.00 and ₹349.95.
The stock has recorded a trading volume of 11,04,335 shares,. Its Average Traded Price (ATP) is ₹318.80, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 313 @ ₹319.70.
Marksans Pharma has an upper circuit limit of ₹379.70 and a lower circuit limit of ₹253.20. The total value traded stands at ₹35.21 CR, and the delivery percentage for the day is 41.02%.
The stock is currently traded with a market lot size of 1. Marksans Pharma also offers a dividend yield of 0.28%.
Marksans Pharma Share Price Chart
Marksans Pharma Share Key Metrics
Volume
11.04 L
Market Cap
14491.63 CR
LTQ@LTP
313@319.70
ATP
318.8
Var Margin
22.27 %
Circuit Range
253.2-379.7
Delivery %
41.02 %
Value
35.21 CR
ASM/GSM
No
Market Lot
1
Marksans Pharma Fundamentals
P/E Ratio
27.76
P/B Ratio
4.51
Div. Yield
0.28
Sector P/E
40.64
Sector P/B
3.51
Sec. Div. Yield
0.51
Marksans Pharma Resistance and Support
Pivot 315.7
Resistance
First Resistance
324.35
Second Resistance
332.25
Third Resistance
340.9
Support
First Support
307.8
Second Support
299.15
Third Support
291.25
Marksans Pharma Historical Data
| Day | Open | Close | Change(%) | Day High | Day Low |
|---|---|---|---|---|---|
| Thu Sep 17 2026 | 315.95 | 319.7 | 1.03% | 322.5 | 312.95 |
| Wed Sep 16 2026 | 311.79 | 316.45 | 1.15% | 323.6 | 307.04 |
| Tue Sep 15 2026 | 330 | 312.85 | -5.02% | 331.39 | 301.1 |
Marksans Pharma Corporate Actions
| Date | Agenda |
|---|---|
| 2026-08-12 | Quarterly Results |
| 2026-05-26 | Audited Results & Final Dividend |
| 2026-02-05 | Quarterly Results |
| 2025-11-13 | Quarterly Results |
| 2025-08-12 | Quarterly Results |
| 2025-05-19 | Audited Results & Final Dividend |
| 2025-02-11 | Quarterly Results |
| 2024-11-12 | Quarterly Results |
| 2024-08-13 | Quarterly Results |
Marksans Pharma News
Marksans Pharma Ltd - 524404 - Voting Results Of The 34Th Annual General Meeting Of The Company
Marksans Pharma's 34th Annual General Meeting approved the financial statements for FY26 and declared a final dividend of Rs.0.90 per equity share. Shareholders also approved the re-appointment of Dr. Sunny Sharma as Director and Mrs. Sandra Saldanha as Whole-time Director for three years, ensuring leadership continuity.
Aug 27 2026 18:57:15
Marksans Pharma Ltd - 524404 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Marksans Pharma received an ESG score of 56 from Crisil ESG Ratings & Analytics Ltd for Fiscal 2026. This voluntary review provides an assessment of the company's environmental, social, and governance practices.
Aug 26 2026 16:16:49
Marksans Pharma Management
| Name | Position |
|---|---|
| Harshavardhan Panigrahi | Company Secretary & Compliance Officer |
| Mark Saldanha | Chairman & Managing Director |
Marksans Pharma Similar Stocks
Molbio Diagnostics Ltd.
1285.30
-21.70 (1.66%)
Concord Biotech Ltd.
1461.10
7.30 (0.50%)
Vijaya Diagnostic Centre Ltd.
1506.10
67.80 (4.71%)
Rainbow Children's Medicare Ltd.
1473.40
16.20 (1.11%)
Natco Pharma Ltd.
818.25
4.95 (0.61%)
CORONA Remedies Ltd.
2169.60
26.00 (1.21%)
Sudeep Pharma Ltd.
1105.40
-1.80 (0.16%)
Alivus Life Sciences Ltd.
1387.80
17.20 (1.25%)
Park Medi World Ltd.
277.90
1.50 (0.54%)
Akums Drugs & Pharmaceuticals Ltd.
766.70
-5.30 (0.69%)
Marksans Pharma FAQs
The Buying Price of Marksans Pharma share is 319.7 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.
To buy Marksans Pharma stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Marksans Pharma, choose your preferred order type, and place the trade.
The Price-to-earnings (P/E) ratio of Marksans Pharma shares is 27.76. You can compare it with the sector average for relative valuation.
The Price to Book (P/B) ratio Marksans Pharma shares is 4.51. Useful to assess the stock's value relative to its book value.
To assess Marksans Pharma’s valuation compare Sector P/E, P/B which are 40.64 & 3.51 with sector averages, along with growth rates and financial metrics.
The Market Cap of Marksans Pharma is 14491.63 CR. It indicates the company's size category and trading liquidity.
The 52 week high and low prices of Marksans Pharma share price is 349.95 & 155.00. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.
Marksans Pharma belongs to the Healthcare sector.
Open Your Free
Demat Account Now!
AMC for First Year- Auto Square Off Charges
13 Lakh+ Clients
Expert-Backed
Premium Tools
Open Your Free
Demat Account Now!
- AMC For First Year
- Account Opening Fee
- 13 Lakh+ Clients
- Expert-Backed
- Premium Tools
Invest in MARKSANS
